硫酸依替米星与硫酸阿米卡星治疗下呼吸道细菌性感染临床评价

Clinical evaluation of the therapeutic effects of etimicin sulfate and amikacin sulfate on bacterial infection in lower respiratory tract

目的 进一步评价硫酸依替米星治疗下呼吸道细菌感染的安全有效性。方法 采用随机对照开放试验方法。硫酸依替米星组 10 0mg溶于生理盐水 10 0ml中静脉滴注 ,每日 2次。硫酸阿米卡星 40 0mg溶于生理盐水 5 0 0ml中静脉滴注 ,每日 1次。疗程均为 5～ 10d。结果 硫酸依替米星组和硫酸阿米卡星组各有 30例评价疗效 ,两组有效率分别为 90 .0 %及 86 .7% ,细菌清除率分别为 88.5 %及88.0 %。两组安全性评价各为 30例 ,耳聋性不良反应分别为 3 .3 %和 3 .3 % ,肾毒性不良反应分别为 3 .3 %和 3 .3 %。两组经统计学处理差异无显著性 (P >0 .0 5 )。

Objective To evaluate the safety and effectiveness of etimicin sulfate and amikacin sulfate on bacterial infection in lower respiratory tract infection.Methods Using the random,contrast and ope test method,in etimicin sulfate group (n=60) 100 mg in 100 ml NS was intravenously given,twice a day;in amikacin sulfate group  (n=60)  400 mg in 500 ml NS was intravenouly given,once a day,with a treatment course of 5～10 days for both groups.Results 30 cases in each group were evaluated for its effectiveness,the effective rates in etimicin sulfate group and in amikacin sulfate group were 90.0% and 86.7% respectively,the clearing bacteria rates were 88.5% and 88.0% respectively.The other 30 cases in each group were evaluated for its safety,the incidences of dys response of deafness were 3.3% and 3.3%,and the incidences of dys response of kidney were 3.3% and 3.3%.There was no significant difference between two group (P>0.05).Conclusion Etimicin sulfate is safe and effective in treating bacterial infection in lower respiratory tract.